CXCL12 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, Agarwall et al found an increased resistance of BM LT-LSCs upon nilotinib treatment that depended on CXCL12 release from MSCs, whereas splenic CML cells were more susceptible to TKI treatment [53].